Immunic (NASDAQ:IMUX) Upgraded to “Strong-Buy” by Leerink Partnrs

Leerink Partnrs upgraded shares of Immunic (NASDAQ:IMUX) to a strong-buy rating in a research report released on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Immunic’s Q3 2024 earnings at ($0.22) EPS, Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.41) EPS.

A number of other research analysts have also recently commented on the company. Piper Sandler restated an overweight rating and issued a $28.00 target price on shares of Immunic in a research note on Tuesday, July 16th. StockNews.com upgraded Immunic from a sell rating to a hold rating in a research report on Tuesday, August 13th. Leerink Partners restated an outperform rating and set a $5.00 price target on shares of Immunic in a research report on Monday. Finally, B. Riley started coverage on Immunic in a research report on Tuesday, August 27th. They set a buy rating and a $6.00 price target on the stock. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Buy and an average price target of $11.20.

Immunic Stock Performance

NASDAQ IMUX opened at $1.52 on Monday. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $1.92. The stock has a 50 day simple moving average of $1.38 and a two-hundred day simple moving average of $1.31. The stock has a market cap of $136.92 million, a P/E ratio of -0.83 and a beta of 1.82.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same period in the previous year, the firm posted ($0.54) earnings per share. Sell-side analysts predict that Immunic will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Immunic

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Immunic in the first quarter worth $9,266,000. Sierra Summit Advisors LLC purchased a new position in shares of Immunic in the fourth quarter worth $487,000. Ikarian Capital LLC raised its stake in shares of Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Immunic in the first quarter worth $25,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.